Complete and Comprehensive Guide to all the Key Facts, Events and Issues of the Last Year Across the Pharmaceutical and Biotechnology Industries.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c79845) has announced the addition of "Scrip Yearbook 2007: 23rd Edition (2 Volumes)" to their offering. Scrip's annual review of the year, Scrip Yearbook 2007, is your guide to all the key facts, events and issues of the last 12 months from across the pharmaceutical and biotechnology industries. Collected and organised from coverage in Scrip World Pharmaceutical News, the respected source of biopharmaceutical industry news, this new updated report provides a complete and concise tool, covering all levels of the industry and recent developments. Scrip Yearbook 2007 will help you to: - Identify which significant mergers and acquisitions were completed - Analyse the strategic and financial performance of your competitors - Track the latest clinical developments and key product launches across all therapeutic areas - Review the latest industry regulations imposed on the industry - Gain insight from leading industry analysts and commentary from senior editors - Keep abreast Verb 1. keep abreast - keep informed; "He kept up on his country's foreign policies" keep up, follow trace, follow - follow, discover, or ascertain the course of development of something; "We must follow closely the economic development is Cuba" ; "trace the of global healthcare initiatives and market movements VOLUME CHAPTER 1 PHARMACEUTICAL COMPANIES 1.1 Pfizer 1.1.1 Financial news 1.1.2 Strategic news 1.1.3 Legal news 1.1.4 Product news 1.1.5 Other news 1.2 Johnson & Johnson 1.2.1 Financial news 1.2.2 Strategic news 1.2.3 Legal news 1.2.4 Product news 1.2.5 Other news 1.3 GlaxoSmithKline 1.3.1 Financial news 1.3.2 Strategic news 1.3.3 Legal news 1.3.4 Product news 1.3.5 Other news 1.4 Bayer 1.4.1 Financial news 1.4.2 Strategic news 1.4.3 Legal news 1.4.4 Product news 1.4.5 Other news 1.5 Sanofi-Aventis 1.5.1 Financial news 1.5.2 Strategic news 1.5.3 Legal news 1.5.4 Product news 1.5.5 Other news 1.6 Novartis 1.6.1 Financial news 1.6.2 Strategic news 1.6.3 Legal news 1.6.4 Product news 1.6.5 Other news 1.7 F Hoffman-La Roche 1.7.1 Financial news 1.7.2 Strategic news 1.7.3 Legal news 1.7.4 Product news 1.8 AstraZeneca 1.8.1 Financial news 1.8.2 Strategic news 1.8.3 Legal news 1.8.4 Product news 1.9 Abbott 1.9.1 Financial news 1.9.2 Strategic news 1.9.3 Legal news 1.9.4 Product news 1.9.5 Other news 1.10 Merck & Co 1.10.1 Financial news 1.10.2 Strategic news 1.10.3 Legal news 1.10.4 Product news 1.10.5 Other news 1.11 Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were 1.11.1 Financial news 1.11.2 Strategic news 1.11.3 Legal news 1.11.4 Product news 1.11.5 Other news 1.12 Wyeth 1.12.1 Financial news 1.12.2 Strategic news 1.12.3 Legal news 1.12.4 Product news 1.12.5 Other news 1.13 Eli Lilly Eli Lilly can refer to:
1.13.1 Financial news 1.13.2 Strategic news 1.13.3 Legal news 1.13.4 Product news 1.13.5 Other news 1.14 Boehringer Ingelheim 1.14.1 Financial news 1.14.2 Legal news 1.14.3 Strategic news 1.14.4 Product news 1.14.5 Other news 1.15 Solvay 1.15.1 Financial news 1.15.2 Strategic news 1.15.3 Legal news 1.15.4 Product news 1.16 Takeda 1.16.1 Financial news 1.16.2 Strategic news 1.16.3 Legal news 1.16.4 Product news 1.16.5 Other news 1.17 Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. 1.17.1 Strategic news 1.17.2 Product news 1.18 Schering-Plough 1.18.1 Financial news 1.18.2 Strategic news 1.18.3 Legal news 1.18.4 Product news 1.19 Astellas 1.19.1 Financial news 1.19.2 Strategic news 1.19.3 Legal news 1.19.4 Product news 1.19.5 Other news 1.20 Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. 1.20.1 Financial news 1.20.2 Strategic news 1.20.3 Legal news 1.20.4 Product news 1.20.5 Other news CHAPTER 2 BIOTECH COMPANIES 2.1 Amgen 2.1.1 Financial news 2.1.2 Strategic news 2.1.3 Legal news 2.1.4 Product news 2.2 Genentech 2.2.1 Financial news 2.2.2 Strategic news 2.2.3 Legal news 2.2.4 Product news 2.3 Genzyme 2.3.1 Financial news 2.3.2 Strategic news 2.3.3 Legal news 2.3.4 Product news 2.4 Serono 2.4.1 Financial news 2.4.2 Strategic news 2.4.3 Legal news 2.4.4 Product news 2.4.5 Other news 2.5 Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec 2.5.1 Financial news 2.5.2 Strategic news 2.5.3 Legal news 2.5.4 Product news 2.6 Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. 2.6.1 Strategic news 2.6.2 Legal news 2.6.3 Product news 2.6.4 Other news 2.7 Medimmune 2.7.1 Strategic news 2.7.2 Product news 2.8 Cephalon Ceph´a`lon n. 1. (Zool.) The head. 2.8.1 Financial news 2.8.2 Strategic news 2.8.3 Legal news 2.8.4 Product news 2.9 Invitrogen 2.9.1 Strategic news 2.9.2 Product news CHAPTER 3 GENERIC COMPANIES 3.1 Teva 3.1.1 Financial news 3.1.2 Strategic news 3.1.3 Legal news 3.1.4 Product news 3.1.5 Other news 3.2 Watson Pharmaceuticals Watson Pharmaceuticals, Incorporated (NYSE: WPI) is the 5th largest pharmaceutical company in the United States based on number of prescriptions dispensed. Based in Corona, California, Watson's Generics division markets over 150 pharmaceutical product families, including one of the 3.2.1 Strategic news 3.2.2 Legal news 3.2.3 Product news 3.3 Mylan Laboratories 3.3.1 Financial news 3.3.2 Strategic news 3.3.3 Product news 3.3.4 Other news 3.4 Pliva 3.4.1 Financial news 3.4.2 Strategic news 3.4.3 Product news 3.4.4 Other news 3.5 Barr Laboratories 3.5.1 Financial news 3.5.2 Strategic news 3.5.3 Legal news 3.5.4 Product news CHAPTER 4 MERGERS & AQUISITIONS 4.1.1 General 4.1.2 Company specific deals VOLUME 2 CHAPTER 1 GEOGRAPHIC OVERVIEW 1.1 World 1.1.1 Regulatory and policy 1.1.2 Market developments 1.1.3 General 1.2 North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. 1.2.1 Regulatory and policy 1.2.2 General 1.3 Canada 1.3.1 Regulatory and policy 1.3.2 General 1.4 US 1.4.1 Regulatory and policy 1.4.2 Market developments 1.4.3 General 1.5 Europe 1.5.1 Regulatory and policy 1.5.2 Market developments 1.5.3 General 1.6 Austria 1.6.1 Regulatory and policy 1.6.2 Market developments 1.7 Belgium 1.7.1 Regulatory and policy 1.8 Czech Republic Czech Republic, Czech Česká Republika (2005 est. pop. 10,241,000), republic, 29,677 sq mi (78,864 sq km), central Europe. It is bordered by Slovakia on the east, Austria on the south, Germany on the west, and Poland on the north. 1.8.1 Regulatory and policy 1.8.2 Market developments 1.8.3 General 1.9 Denmark 1.9.1 Regulatory and policy 1.9.2 Market developments 1.9.3 General 1.10 Finland 1.10.1 Regulatory and policy 1.10.2 Market developments 1.11 France 1.11.1 Regulatory and policy 1.11.2 Market developments 1.12 Germany 1.12.1 Regulatory and policy 1.12.2 Market developments 1.12.3 General 1.13 Greece 1.13.1 Regulatory and policy 1.13.2 Market developments 1.14 Hungary 1.14.1 Regulatory and policy 1.14.2 Market developments 1.14.3 General 1.15 Ireland 1.15.1 Regulatory and policy 1.15.2 Market developments 1.15.3 General 1.16 Italy 1.16.1 Regulatory and policy 1.16.2 Market developments 1.17 The Netherlands 1.17.1 Regulatory and policy 1.18 Norway 1.18.1 Regulatory and policy 1.19 Poland 1.19.1 Regulator 1.19 Poland 1.19.1 Regulatory and policy 1.19.2 Market developments 1.19.3 General 1.20 Portugal 1.20.1 Regulatory and policy 1.20.2 Market developments 1.20.3 General 1.21 Romania 1.21.1 Regulatory and policy 1.21.2 Market developments 1.22 Russia 1.22.1 Regulatory and policy 1.22.2 Market developments 1.22.3 General 1.23 Spain 1.23.1 Regulatory and policy 1.23.2 Market developments 1.23.3 General 1.24 Sweden 1.24.1 Regulatory and policy 1.24.2 Market developments 1.25 Switzerland 1.25.1 Regulatory and policy 1.25.2 Market developments 1.25.3 General 1.26 Turkey 1.26.1 Regulatory and policy 1.27 United Kingdom 1.27.1 Regulatory and policy 1.27.2 Market developments 1.27.3 General 1.28 Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. 1.28.1 Market developments 1.29 Argentina 1.29.1 Regulatory and policy 1.29.2 Marketing developments 1.30 Brazil 1.30.1 Regulatory and policy 1.30.2 Market developments 1.31 Colombia 1.31.1 Regulatory and policy 1.32 Mexico 1.32.1 Regulatory and policy 1.33 Puerto Rico Puerto Rico (pwār`tō rē`kō), island (2005 est. pop. 3,917,000), 3,508 sq mi (9,086 sq km), West Indies, c.1,000 mi (1,610 km) SE of Miami, Fla. 1.33.1 Regulatory and policy 1.34 Asia 1.34.1 Regulatory and policy 1.34.2 Market developments 1.34.3 General 1.35 Australia 1.35.1 Regulatory and policy 1.35.2 Market developments 1.35.3 General 1.36 China 1.36.1 Regulatory and policy 1.36.2 Market developments 1.36.3 General 1.37 India 1.37.1 Regulatory and policy 1.37.2 Market developments 1.38 Indonesia 1.38.1 Regulatory and policy 1.39 Japan 1.39.1 Regulatory and policy 1.39.2 Market developments 1.39.3 General 1.40 Philippines 1.40.1 Regulatory and policy 1.41 South Korea 1.41.1 Regulatory and policy 1.41.2 Market developments 1.41.3 General 1.42 Taiwan 1.42.1 Regulatory and policy 1.43 Africa 1.43.1 Regulatory and policy 1.44 South Africa South Africa, Afrikaans Suid-Afrika, officially Republic of South Africa, republic (2005 est. pop. 44,344,000), 471,442 sq mi (1,221,037 sq km), S Africa. 1.44.1 Regulatory and policy CHAPTER 2 DISEASE PREVALENCE 2.1 Anti-infectives 2.1.1 Tuberculosis 2.1.2 Measles measles or rubeola (r  bē`ələ), highly contagious disease of young children, caused by a filterable virus and spread by droplet spray from the nose, mouth, , mumps and rubella rubella or German measles, acute infectious disease of children and young adults. It is caused by a filterable virus that is spread by droplet spray from the respiratory tract of an infected individual.
2.2 Cancer 2.2.1 Cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. 2.2.2 Colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. 2.2.3 Leukaemia 2.3 Immunological 2.3.1 HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome 2.4 Metabolic 2.4.1 Diabetes 2.4.2 Obesity 2.5 Parasitics 2.5.1 Malaria CHAPTER 3 CLINICAL TRIALS 3.1 General 3.2 Anti-infectives 3.2.1 Antibiotics 3.2.2 HIV/AIDS 3.2.3 Hepatitis 3.3 Cancer 3.3.1 General 3.3.2 Breast cancer 3.3.3 Cervical cancer 3.3.4 Colorectal cancer 3.3.5 Leukaemia 3.3.6 Lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. 3.3.7 Pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. 3.4 Cardiovascular 3.4.1 General 3.4.2 Cholesterol 3.4.3 Hypertension 3.5 Genitourinary genitourinary /gen·i·to·uri·nary/ (jen?i-to-u´ri-nar-e) pertaining to the genital and urinary organs. gen·i·to·u·ri·nar·y adj. Abbr. 3.5.1 Erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. 3.6 Immunological 3.6.1 General 3.7 Metabolic 3.7.1 Diabetes 3.8 Musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles. mus·cu·lo·skel·e·tal adj. Relating to or involving the muscles and the skeleton. 3.8.1 Osteoporosis 3.8.2 Rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. 3.9 Neurological neurological, neurologic pertaining to or emanating from the nervous system or from neurology. neurological assessment evaluation of the health status of a patient with a nervous system disorder or dysfunction. 3.9.1 Alzheimer's 3.9.2 Migraine migraine (mī`grān), headache characterized by recurrent attacks of severe pain, usually on one side of the head. It may be preceded by flashes or spots before the eyes or a ringing in the ears, and accompanied by double vision, nausea, 3.9.3 Multiple sclerosis 3.9.4 Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. 3.9.5 Schizophrenia 3.9.6 Stroke 3.10 Ophthalmological oph·thal·mol·o·gy n. The branch of medicine that deals with the anatomy, functions, pathology, and treatment of the eye. oph·thal 3.11 Parasitics 3.11.1 Malaria 3.12 Respiratory 3.12.1 Asthma 3.12.2 Chronic Obstructive Pulmonary Disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ) 3.12.3 Smoking cessation smoking cessation Public health Temporary or permanent halting of habitual cigarette smoking; withdrawal therapies–eg, hypnosis, psychotherapy, group counseling, exposing smokers to Pts with terminal lung CA and nicotine chewing gum are often ineffective. CHAPTER 4 PATENTS AND INTELLECTUAL PROPERTY 4.1 Pfizer 4.2 Johnson & Johnson 4.3 GlaxoSmithKline 4.4 Bayer 4.5 Sanofi-Aventis and Bristol-Myers Squibb 4.6 Sanofi-Aventis 4.7 Bristol-Myers Squibb 4.8 Novartis 4.9 F Hoffman-La Roche 4.10 AstraZeneca 4.11 Abbott 4.12 Merck & Co 4.13 Wyeth 4.14 Eli Lilly 4.15 Takeda 4.16 Astellas 4.17 Amgen 4.18 Genentech 4.19 Gilead Sciences 4.20 Medimmune 4.21 Cephalon 4.22 Invitrogen 4.23 Teva 4.24 Watson Pharmaceuticals 4.25 Mylan Laboratories 4.26 Barr Laboratories CHAPTER 5 DRUG DELIVERY 5.1 Buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal 5.2 Controlled release 5.3 Drug-eluting stents 5.4 Encapsulated 5.5 Extended release 5.6 Gene/DNA delivery 5.7 Immediate release 5.8 Implanted 5.9 Inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. 5.10 Injected 5.11 Liposomal 5.12 Nanotechnology 5.13 Nasal 5.14 Needle-free 5.15 Ocular ocular /oc·u·lar/ (ok´u-lar) 1. of, pertaining to, or affecting the eye. 2. eyepiece. oc·u·lar adj. 1. Of or relating to the eye or the sense of sight. 5.16 Oral 5.17 Orally disintegrating 5.18 Parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. 5.19 Pulmonary 5.20 Targeted 5.21 Taste-masking 5.22 Transdermal CHAPTER 6 APPROVALS Companies mentioned: - Pfizer - Johnson & Johnson - GlaxoSmithKline - Bayer - Sanofi-Aventis - Novartis - F Hoffman-La Roche - AstraZeneca - Abbott - Merck & Co - Bristol-Myers Squibb - Wyeth - Eli Lilly - Boehringer Ingelheim - Solvay - Takeda - Baxter International - Schering-Plough - Astellas - Merck KGaA - Amgen - Genentech - Genzyme - Serono - Biogen Idec - Gilead Sciences - Medimmune - Cephalon - Invitrogen - Teva - Watson Pharmaceuticals - Mylan Laboratories - Pliva - Barr Laboratories Source: Informa Healthcare For more information visit http://www.researchandmarkets.com/reports/c79845 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion